We suggest that persistent residual signaling of both p70S6K and 4EBP1 following anti-HER2 treatment in low PPP2R2B-expressing cancer cells might collaterally confer treatment failure, though its correlation with clinical resistance to anti-HER2 therapy needs futher validated in clinical samples. Here, ERBB2 is linked to cancer.